<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03088735</url>
  </required_header>
  <id_info>
    <org_study_id>SMD-2017-03</org_study_id>
    <nct_id>NCT03088735</nct_id>
  </id_info>
  <brief_title>Transfer Strategy in an Oocyte Donation Programme</brief_title>
  <official_title>Pilot Study of the Best Transfer Strategy in an Oocyte Donation Programme: an Intention to Treat Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Universitari Dexeus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Universitari Dexeus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has been previously shown that although the activation of the embryonic genome can begin&#xD;
      as early as two days of initiation of the embryonic development (D2), it is expressed on day&#xD;
      3 (D3). Without this activation, the embryo can not continue its development. Therefore, it&#xD;
      has been suggested that extended culture to blastocyst stage could be an option to identify&#xD;
      and better select embryos that have been able to carry out this activation. The purpose of&#xD;
      this study is to compare cumulative pregnancy and live birth rates following transfer of&#xD;
      cleavage embryos or blastocysts.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to the clinically and statistically significant inferior results for the D3 group following&#xD;
    evaluation by the institutional review board.&#xD;
  </why_stopped>
  <start_date type="Actual">April 5, 2017</start_date>
  <completion_date type="Actual">August 31, 2019</completion_date>
  <primary_completion_date type="Actual">August 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative live birth rate</measure>
    <time_frame>at 12 months after a embryo transfer (time considered enough in order to do a minimum of one frozen-thawed cycle if pregnancy is not achieved with the fresh cycle</time_frame>
    <description>Total number of births considering fresh and frozen thawed embryos transferred</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative pregnancy rate</measure>
    <time_frame>at 12 months after a embryo transfer (time considered enough in order to do a minimum of one frozen-thawed cycle if pregnancy is not achieved with the fresh cycle</time_frame>
    <description>Total number of pregnancies confirmed by ultrasound 6 weeks after embryo transfer including fresh and thawed embryos.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Oocyte Donation</condition>
  <condition>Infertility, Female</condition>
  <condition>Embryo Transfer</condition>
  <arm_group>
    <arm_group_label>Blastocyst-stage embryo transfer strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cleavage-stage embryo transfer strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blastocyst-stage embryo transfer strategy</intervention_name>
    <description>Intra-uterine transfer of blastocist if in cleavage embryo stage the oocyte recipient has a m√≠nimum of 3 availables embryos with at least one of good quality to transfer and also the inta-uterine transfer of cleavage embryo (day 3) when the recipient doesn't have the previous criteria.</description>
    <arm_group_label>Blastocyst-stage embryo transfer strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cleavage-stage embryo transfer strategy</intervention_name>
    <description>Inta-uterine transferring of cleavage embryo transfer (day 3 of develpment) in oocyte recipients</description>
    <arm_group_label>Cleavage-stage embryo transfer strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients under their first or second cycle of a synchronous (fresh) oocyte donation&#xD;
             cycle.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Preimplantation genetic screening or diagnosis cycles.&#xD;
&#xD;
          -  Patients with strict blastocyst-stage embryo transfer indication by the couple's&#xD;
             treating physician.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department Obstetric, Gynecologic and Reproductive Medicine</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelons</state>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.dexeus.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 18, 2017</study_first_submitted>
  <study_first_submitted_qc>March 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut Universitari Dexeus</investigator_affiliation>
    <investigator_full_name>Elisabet Clua Obrado</investigator_full_name>
    <investigator_title>Head of Gamete and Embryo Donation</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

